Although the syngeneic murine models serve as the workhorse in cancer immunology.87 for candidate immunotherapeutic drugs development88 and mechanism study,89 these models often inadequately replicate human tumor immunobiology, particularly in microbiome-dependent contexts.90 Therefore, we try to utilize the CD34+ hematopoietic stem cells reconstituted humanization model to evaluate the effect of MNC-168, our data suggest that MNC-168 retains efficacy in a human immune context. The gene discussed is CD34; the disease is cancer.